IVAX to Meet or Exceed Consensus Analysts' Expectations for Fourth Qu

    Business Editors/Health/Medical Writers

    MIAMI--(BUSINESS WIRE)--Jan. 11, 2005--IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced today that it expects to meet or exceed consensus analysts' expectations of $.19 earnings per share for the fourth quarter 2004.
    IVAX expects to release its fourth quarter 2004 and year 2004 financial data in mid-March 2005. IVAX expects to provide earnings guidance for 2005 by then or earlier.
    IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally.
    Copies of this and other news releases may be obtained free of charge from IVAX' website at http://www.ivax.com.
    Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements, including, among others, statements relating to goals, plans, expectations, estimates and projections regarding the company's financial position, results of operations, market position and business strategy involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the risks that IVAX may not meet or exceed consensus analysts' estimates for the fourth quarter; that IVAX may not release its fourth quarter and year 2004 financial data in mid-March 2005; and that IVAX may not provide earnings per share guidance for the year 2005 on or before that date. In addition to the risk factors set forth above, IVAX' forward-looking statements may also be adversely affected by general market factors; product availability; federal and state regulations and legislation, including changes in accounting regulations; the regulatory process for new products and indications; manufacturing issues that may arise; trade buying patterns; exchange rate fluctuations; patent positions and the timing and outcome of legal proceedings; changing market conditions; the availability and cost of raw materials and other third party products; the impact of competitive products and pricing; and other risks and uncertainties based on economic, competitive, governmental, technological and other factors. For further details and discussion of these and other risks and uncertainties, see IVAX' Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. IVAX undertakes no obligation to publicly update any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

--30--JD/mi*

CONTACT: IVAX Corporation, Miami David Malina, 305-575-6043

KEYWORD: FLORIDA INDUSTRY KEYWORD: PHARMACEUTICAL SOURCE: IVAX Corporation

Copyright Business Wire 2005